SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Nuvo Research Inc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Montana Wildhack who wrote (6744)2/12/2001 10:21:46 AM
From: Cal Gary  Read Replies (1) of 14101
 
HI Wolf, I hear your. Great answer.

These projections were based around 5% as a means of
measuring how little it would take to make Dimethaid viable.


The sales of Celebrex and Vioxx plus other NSAIDs do give accurate market size numbers.

What Celebrex and Vioxx tells me is doctors will Quickly switch to safer and effective treatments, especially in the case of OA suffers.

To temper this, the majority of their sales is in North America, so far. Therefore I should reword. NA doctors tend to quickly switch to safer and effective treatments, especially in the case of OA suffers. I hope this holds true with European doctors.

Remember, Celebrex has recently begun ramp up in Europe, so DMX will soon meet head to head for the attention/decision of EU physicians. The positive thing is Pennsaid is not competing for use with established Celebrex clients. I know one Celebrex user who will stick with his doctors recommendation / plan until it was completed before switching or trying anything else.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News